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Recent epidemiologic studies evidence a dramatic increase of cardiovascular diseases, especially associated with the aging of the
world population. During aging, the progressive impairment of the cardiovascular functions results from the compromised
tissue abilities to protect the heart against stress. At the molecular level, in fact, a gradual weakening of the cellular processes
regulating cardiovascular homeostasis occurs in aging cells. Atherosclerosis and heart failure are particularly correlated with
aging-related cardiovascular senescence, that is, the inability of cells to progress in the mitotic program until completion of
cytokinesis. In this review, we explore the intrinsic and extrinsic causes of cellular senescence and their role in the onset of these
cardiovascular pathologies. Additionally, we dissect the effects of aging on the cardiac endogenous and exogenous
reservoirs of stem cells. Finally, we offer an overview on the strategies of regenerative medicine that have been advanced in the
quest for heart rejuvenation.
1. Introduction
Cardiovascular diseases affect millions of patients world-
wide and are the primary cause of mortality and comor-
bidities. Thanks to the incredible technological progress
realized in the post second war period (1945–1964) in the
Western countries, a whole generation of people started to
benefit increased wealth and ameliorated life quality and
expectancy [1].
For this generation and those to come, the prolonged life-
span is associated with a dramatic increase of cardiovascular
diseases, mainly related to aging. This is at least partly due to
a progressive impairment of the cellular processes regulating
cardiac and vascular homeostasis, finally leading to the
development of cardiovascular pathologies. In fact, the
molecular mechanisms that protect the heart against stress
are downregulated by aging, making the myocardium more
susceptible to injury. Pathologies, as atherosclerosis, cardiac
fibrosis, and cardiomyopathy, are often linked to the failure
of cardiovascular tissue cells to reenter the cell cycle, namely,
senescence, due to endogenous or exogenous causes.
This review will focus on the cardiovascular pathologies
correlated to senescence, the effect of aging on the cardiac
endogenous resources of stem cells, and the potential strate-
gies of regenerative medicine to be applied to maintain the
heart younger and healthier.
2. Positive and Negative Effects of
Senescence on Cardiovascular Disease
Onset and Progression
Cellular senescence has been for long time an underestimated
biological process, even after its discovery in 1961 by Hayflick
and Moorhead [2]. As demonstrated by the growing body of
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literature in the latest years, senescence is an important func-
tion involved in the maintenance of tissue homeostasis, as
well as the more extensively studied apoptosis.
Mitotic cells might undergo senescence by failing to
replicate. Unlike the quiescence state, in which cells are
reversibly dormant, senescence takes place in cells with
an active metabolism that had entered the cell cycle but
got stopped at G1 phase by the action of specific inhibitors
(as reviewed in [3]).
While it is commonly accepted as an aging-related
phenomenon, senescence might happen also during the
embryonic development with the biological meaning of
replacing transient structures or specific cell types with other
ones [3–5]. This is partly conflicting with the hypothesis of
antagonistic pleiotropy as an evolutionary justification for
senescence. In fact, it was George J. Williams to observe as
first that it could be described as an adaptive event during
evolution, since some genetic traits demonstrated to be
beneficial in the initial life stages, but disadvantageous in
the elderlies [6].
Senescence in adult tissues can be classified in two main
subcategories, based on the underlying molecular mecha-
nism: replicative (or intrinsic), caused by telomere shorten-
ing, and stress-induced, in response to reactive oxygen
species (ROS) and/or oncogenes [7–9].
Activation of the cellular senescence genetic program
prompts a series of molecular changes, mostly affecting
cell cycle, extracellular matrix (ECM), secretion of growth
factors, and inflammatory mediators.
A more detailed description of the triggering stimuli and
molecular pathways involved in the pathogenesis of several
cardiovascular diseases will be provided below.
Senescent cells might be easily recognized in culture by
typical morphological features, that is, flatness, enlargement,
vacuolization, multinucleation, and progressively reduced
proliferation.
Hallmarks of cellular senescence are represented by lyso-
somal immunodetection of β-galactosidase activity (also
known as senescence-associated β-galactosidase activity),
lipofuscin rendered evident after Sudan black B staining,
downregulation of proliferation markers, for example, phos-
phohistone 3 and Ki-67, reduced incorporation of 5-bromo-
deoxyuridin, identification of heterochromatin foci, and
increased expression of senescence mediators (e.g., p15,
p16, p21, p27, and ARF) and metalloproteinases. As previ-
ously mentioned, a further phenotypic characteristic of
senescent cells is their secretion of several specific proinflam-
matory cytokines and growth factors (e.g., IL-6, IL-8, and
TGF-β) [10]. Endowed with this senescence-associated
secretory phenotype (SASP), cells exert a paracrine effect on
neighboring cells, as well as an autocrine conditioning [11].
Consequently, the role of senescence in a variety of
pathologies has been increasingly studied in the last years.
Among cardiovascular diseases, atherosclerosis and heart
failure are those whose progression has been shown to be
most deeply associated with cellular senescence.
2.1. Atherosclerotic Lesions. Senescence-associated alterations
are commonly observed in vascular cells harvested from
atherosclerotic regions [12–16]. Atherosclerosis is a chronic
inflammatory vascular disease that evolves from an initial
dysfunction of the intimal endothelial layer to a progressive
development of advanced atherogenic plaques [17].
High blood cholesterol levels, inflammatory cytokines,
growth factors, angiotensin II, and hyperglycemia, with its
associated advanced glycation end products (AGEs), are
powerful extrinsic stimuli for vascular cell senescence [17].
Telomere shortening and activation of the Ras pathway are
regarded as intrinsic vascular senescence triggers [17].
In addition, mitochondria have been revealed to play an
important role in the development of atherosclerotic lesions.
In fact, mitochondrial dysfunction, mtDNA mutations, and/
or release of mitochondria-specific ROS in both senescent
endothelial and smooth muscle cells are considered as further
putative causes of atherogenesis [18].
As recently reviewed [19, 20], the molecular basis for
aging of vascular cells involves several genes (as Klotho)
and proteins (e.g., Sirtuins, progerin, JunD, p66shc, and β-
amyloid peptides).
Replicative senescence in vascular cells activates molecu-
lar pathways similar to those triggered after DNA damages
caused by external agents. The stress-induced typology is also
frequently found in endothelial and smooth muscle cells
from atherosclerotic tissues. A variety of pathways are inter-
ested in vascular DNA damage-induced cellular senescence,
most converging on the activation of cyclin-dependent
kinase inhibitors (p15, p16, p21, p27, and/or p53). The medi-
ators of cell cycle progression are conversely downregulated,
for example, derepressing the gene encoding for cyclin-
dependent kinase inhibitor 2A. This prevents cyclin-
dependent kinases (1, 2, 4, and 6) and cyclins (A, E, and D)
to downregulate tumor suppressor RB. Consequently, the
vascular cell is arrested at the Gap 1 phase of the mitotic
replication cycle (as reviewed in [3]).
In addition to mentioned DNA damage-related path-
ways, activation of nuclear factor NF-κB and CCAAT/
enhancer-binding protein-β pathways is required by the
senescent vascular cells to activate SASP program, which
includes the secretion of IL-6, IL-8, chemokines, and activa-
tors of macrophages and monocytes (MCP, MIP, TNF-α,
TGF-β, and GM-CSF) as well as ECM proteases [3, 21].
Interestingly, smooth muscle cells secrete also procalcific fac-
tors, such as RUNX-2, alkaline phosphatase, collagen I,
matrix GLA protein, and BMP-2 [12, 22].
The proteolytic secretome of vascular smooth muscle
cells, together with ROS and the enzymes released by
recruited macrophages, contributes to undermining plaque
stability in the atherosclerotic cap region through ECM
remodeling [23].
Moreover, also endothelial nitric oxide synthase (eNOS)
and prostacyclin pathways result impaired in the senescent
endothelial cells from atherogenic regions [14, 24–26].
Growing evidence suggests a crosstalk between nitric
oxide (NO) signaling and the occurrence of oxidative stress
in the onset and progression of age-related vascular diseases,
such as hypertension, heart failure, ischemia, and stroke.
Consequently, NO is being considered as an emerging
molecular target for the development of new therapeutic
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strategies for cardio- and cerebrovascular pathologies, par-
ticularly in aged patients. Accordingly, nowadays, several
natural-derived compounds or pharmacological inhibitors
are being proposed as modulators of NO-mediated path-
ways in this population. Curiously, vascular senescence is
thought to have beneficial effects in the evolution of
atherosclerosis. In particular, polymorphism analyses in
humans and in atherosclerotic murine models revealed that
lower levels of cyclin-dependent kinase inhibitors, especially
CDKN1 and CDKNA2, are associated with increased pro-
pensity to develop atherogenic lesions [27, 28]. In other
genome-wide associated studies, a link between aortic aneu-
rysms and the polymorphisms for CDKNA2 and CDKNB2
has been shown [29].
On the other hand, other studies are supportive of a view
of pathologic deterioration induced by senescent vascular
cells. In fact, endothelial cells with an activated senescence
program secrete high levels of ICAM-1, PAI-1, and IL-1α
and show a reduced ability to metabolize lipids [30–33],
which is likely to aggravate atherosclerosis.
It has been recently demonstrated that endothelial SASP,
and in particular its microvesicular component, is able to
stimulate the onset of calcification through the overexpres-
sion of bone-related proteins, for example, annexins and
BMPs, and the increase of Ca2+ content too [34].
Typical hallmarks, triggers, and effects of vascular senes-
cence in atherosclerosis have been summarized in Table 1.
2.2. Heart Failure. A potentially predictive biomarker of
cardiovascular senescence is leukocyte telomere length.
Remarkably, its shortening is associated with several cardio-
vascular diseases, among which are atherosclerosis, aortic
valve stenosis, and thrombogenesis. Moreover, it is also
linked to the main risk factors for these pathologies, such as
hypercholesterolemia and hypertension. Leukocyte telomere
length correlates inversely with plaque progression, but also
heart failure (HF), a severe chronic condition characterized
by dilation and decreased thickness of the ventricular wall.
HF is the final stage of all cardiovascular diseases and
results in a progressive weakening of the global cardiac
function, which is related to the dysfunctional hypertrophic
and apoptotic state of the terminally differentiated cardiac
myocytes [33, 35–40].
Besides apoptosis, autophagy is as well a crucial mecha-
nism for maintaining cellular homeostasis during aging,
since it ensures the removal of dysfunctional organelles and
misfolded proteins that dramatically increase in aged organs.
Generally, elderly patients have reduced levels of autophagy,
probably due to the elevation of oxidative stress. In this
regard, it has been demonstrated that cardiac-specific dele-
tion of Atg5 in mice associates with early signs of senescence,
accumulation of dysfunctional mitochondria, disorganiza-
tion of sarcomere structure, and age-related cardiomyopathy
[41]. Similarly, mice deficient in Parkin gradually showed a
decrease in cardiac function and survival [42]. Coherently,
Table 1: Senescence in atherosclerotic lesions.
Extrinsic vascular senescence triggers
(i) High blood cholesterol levels
[17]
(ii) Inflammatory cytokines and growth factors
(iii) Angiotensin II
(iv) Hyperglycemia and associated AGEs
Intrinsic vascular senescence triggers
(i) Telomere shortening
[17]
(ii) Activation of Ras pathway
(iii) Mytochondrial dysfunction, mtDNA mutations, and/or release of mitochondria-specific ROS [18]
Activated (↑) and inactivated (↓) molecular pathways and functions
(i) Involvement of several genes (e.g., Klotho) and proteins (e.g., Sirtuins, progerin, JunD, p66shc, and β-amyloid peptides)
[3]
(ii) ↑ DNA damage signaling
(a) ↑ cyclin-dependent kinase inhibitors (p15, p16, p21, p27, and/or p53)
(b) ↓ mediators of cell cycle progression (cyclin-dependent kinase inhibitor 2A; cyclin-dependent kinases
(1, 2, 4, and 6) and cyclins (A, E, and D))
(c) ↓ tumor suppressor RB
(iii) ↑ nuclear factor NF-κB and CCAAT/enhancer-binding protein-β pathways [3, 21]
(iv) ↑ SASP program, which includes the secretion of IL-6, IL-8, chemokines, and activators of macrophages and
monocytes (MCP, MIP, TNF-α, TGF-β, and GM-CSF), as well as ECM proteases
[3, 21]
(v) ↑ procalcific factors (RUNX-2, alkaline phosphatase, collagen I, matrix GLA protein, and BMP-2) in SMCs [12, 22]
(vi) Impairment of eNOS and prostacyclin pathways in senescent ECs [14, 24–26]
(vii) Association between decreased levels of CDKN1 and CDKNA2 and increased propensity to develop atherosclerosis [27, 28]
(viii) Link between CDKN1 and CDKNB2 polymorphisms and aortic aneurism [29]
(ix) ↑ ICAM-1, PAI-1, and IL-1α and ↓ lipid metabolism ability in ECs [30–33]
(x) ↑ SASP secretion of annexins and BMPs and ↑Ca2+ in ECs favors calcification onset [34]
AGEs: advanced glycosylation end products; SMCs: smooth muscle cells; ECs: endothelial cells.
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experimental evidence suggests that the modulation of
autophagy may slow down or prevent cardiac aging. For
example, stimulation of mitophagy (i.e., autophagy of mito-
chondria) with spermidine, a natural polyamine, was found
to preserve cardiac function in old mice [43, 44]. Similarly,
inhibition of miR-22, whose expression was reported to be
elevated in the aged myocardium in parallel to decreased
autophagic activity, rescues autophagy and improves cardiac
function in old mice [45, 46].
Alterations of the inflammatory, endothelial, and myo-
genic phenotype of cardiac cells are also observed in senes-
cence events occurring in the failing heart. In particular,
most of these changes are related to the aging-dependent
manifestation of mutations in genes involved in the calcium
cycling and signaling. The activity of sarcoplasmic reticulum
calcium adenosine triphosphatase, that is, SERCA2, and cal-
sequestrin is drastically decreased during aging [47, 48], due
to the lower level of expression of these proteins. Similarly,
also Ica, that is, the L-type calcium current, is reduced and
often completely inactivated. In this condition, the sarcoplas-
mic reticulum has a considerably diminished calcium con-
centration and, consequently, calcium transient amplitude
and propagation result were impaired.
Nevertheless, also other pathways involved in heart rate
modulation might be compromised by aging, for example,
as cardiac sympathetic innervation. In fact, the catechol-
amine uptake is reduced in senescent cardiac neuronal cells
as well as it is the response to isoproterenol [49]. In particu-
lar, the decreased epinephrine reuptake is physiologically
compensated by the reduction of the arterial baroreflex
response [49]. Moreover, noradrenalin transporter is down-
regulated in aging, causing an impairment in the neurotrans-
mitter reuptake and a consequent reduction of its positive
inotropic effect [50].
The human K+ channel ether-à-go-go gene (hERG)
might also be interested by age-dependent mutations caus-
ing rhythm instabilities, as well as disorganization of the
structure of the sarcomeric structure and myofibrillary
proteins, as evidenced in a mouse model of a mutated
hERG homolog [51].
However, all these aging-related impairments increase
the vulnerability of the single cells and hence of the whole
myocardium to develop arrhythmic events. In fact, these
occurrences are typical of elderly patients, which are there-
fore submitted to ICD implantation.
In addition to cardiac myocytes and neuronal cells, senes-
cence affects also the vascular compartment, for example,
compromising coronary microcirculation.
Cardiomyopathy-induced HF has very similar signs to
those described for atherosclerosis. Furthermore, it has
been shown that aging downregulates the mitochondrial
nicotinamide adenine nucleotide histone deacetylase (SIRT)
3, which is associated with pericyte loss and endothelial
dysfunction, further exacerbated in the case of concomitant
diabetic condition [52].
In the presence of risk factors, such as obesity, aging-
related microvascular rarefaction is correlated to adipose
tissue activation of the ADAM 17/TACE gene, encoding
for a metalloproteinase that is able to cleave out the active
TNF-α polypeptide from pro-TNF-α. ADAM-17/TACE
overexpression is also facilitated by the loss of negative
regulation by caveolin-1, analogously decreased in aged
obese patients [53].
In acute settings of cardiac ischemia, the activation of
the senescence-associated genetic program in recruited
fibroblasts can be considered a protective mechanism from
endothelin-1-mediated cardiac fibrosis [54, 55].
Table 2 offers a schematic overview on the classic signs,
causes, and consequences of senescence in heart failure
settings.
A detailed description of age-related events that irre-
versibly compromise heart functionality is provided in
these suggested review articles [3, 20, 56].
Moreover, other cardiovascular pathologies, as aneu-
rysms and peripheral artery disease, have a strong correlation
with the onset of senescence in the cellular and ECM compo-
nents of interested tissues and might be implicated in the
genesis of heart failure [57–62].
3. Tissue Development, Regeneration, and
Aging in the Heart
During ontogenesis, the heart originates from the mesoder-
mal tissue of the embryonic cardiogenic plate. From this,
the primitive cardiac tube develops, loops and twists, and
finally forms the atria, ventricles, and outflow tracts [63].
More accurately, two heart fields in strict vicinity and
relation constitute the primitive cardiac tissue. In particular,
the cellular elements of the cardiac crescent, or anterior heart
field, will mainly develop the left ventricle and the atria, while
the ones of the second heart field will mainly colonize the
right ventricle and the outflow tract, with small contribution
to the atria [64]. Indeed, the cells contributing to the develop-
ment of the heart originate from several sources. As recently
demonstrated, Isl-1 progenitors will give rise to the atria and
outflow tract by following different specializations. The
expression in Isl-1 progenitors of the cardiac-specific homeo-
box Nkx2.5 and of the patterning gene Wnt-2 is associated
with the differentiation towards the atrial phenotype. For
the development of the outflow tract and right ventricle,
the same progenitors acquire a different phenotype, express-
ing Nkx2.5, the myocyte-specific gene Mef2-c, the tran-
scription factor gene T-box 1, and the fibroblast growth
factor genes Fgf-8/10. Other Isl-1 cells, coexpressing the
early endothelial marker Flk-1, are more involved in the
formation of the endothelial lining in the endocardial layer
or in the vessels. In the immediate postnatal life, Isl-1 cells
and cardioblasts progressively differentiate into mature
cardiomyocytes [64, 65].
Additional cell types with immature and plastic charac-
teristics have been identified in the heart. In particular,
cardiac stem cells and progenitors have been detected and
isolated from pediatric and adult heart tissues. These cells
express a typical hematopoietic marker, that is, c-kit, in com-
bination with other proteins and transcription factors, for
example, the hematopoietic Sca1, CD34, and/or the more
cardiac-committed Mef2-c and GATA-4 or the endothelial
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CD31. Cardiac stem cells have been shown to possibly origi-
nate all the lineages of the heart [66–70].
Further cells of particular interest in the heart tissues
are the epicardial stem cells. As by their name, these cells
can be retrieved in the epicardium and are identified by
the expression of the Wilms tumor protein, codified by
the gene Wt1 [71].
Exogenous cells with plastic features can participate in
the organ development also in other phases. Neural crest cel-
lular elements contribute to the construction of the distal
outflow tract, working myocardium, glia, and nervous tissue
during late gestation [72]. Additionally, endothelial progeni-
tor cells are involved in the formation of new vessels in adult
life [73].
Despite the existence of several cardiac stem cells and
progenitors, the heart is not able to undergo a sustained
self-renewal, especially after extensive damage. This property
is related to its primary function, that is, pumping the blood
throughout the whole body, which consumes massive
amount of energy resources.
In the final stages of gestation, neonatal cardiomyo-
cytes withdraw from reentering the cell cycle. Indeed, in
the immediate postnatal period, cells undergo an incom-
plete mitosis and can be seen in the myocardium having
dual or multiple nuclei, due to the inability to progress
in karyo- or cytokinesis [74, 75]. In fact, they modify their
growth modality from hyperplastic to hypertrophic and
will not reenter the cell cycle. Actually, Ahuja et al. demon-
strated that a preparatory dedifferentiation process, consist-
ing of cycles of myofibrillary disassembly and reassembly, is
necessary for a cardiomyocyte to divide [76]. However, a
study of genetic cell fate mapping by Zhang et al.’s group
revealed that mouse mature cardiomyocytes are able
in vitro to undergo dedifferentiation-proliferation and show
multipotent capacities [68].
Cardiac stem cells maintain their plastic ability during
adult life, but remain quiescent in special microenviron-
ments, namely, the cardiac niches, and are reactivated to
replace the physiological loss of cardiomyocytes. However,
the reactivation of the cell cycle only in cardiac stem cells is
not sufficient to face the large loss of cardiac myocytes that
occurs after an ischemic attack.
The sustained metabolic conversion of the heart is
emblematic of mammalian species, but not of other verte-
brates. Salamanders, axolotls, and zebrafish respond to heart
injury inducing a blastema tissue, as part of an epimorphic
regeneration [77]. This program is realized through the
cell-cycle activation in mature cardiomyocytes, the degrada-
tion of the ECM, and a relatively low inflammatory response,
mediated by a deficient adaptive immunity [78], in a tissue
Table 2: Senescence in heart failure.
Extrinsic heart senescence triggers
(i) Hypercholesterolemia
[33, 36–40]
(ii) Hypertension
Intrinsic heart senescence triggers
(i) Leukocyte telomere length shortening [33, 36–40]
Upregulated (↑) and downregulated (↓) molecular pathways and functions
(i) ↓ autophagy, mediated by ↑ oxidative stress
(a) Early signs of senescence, accumulation of dysfunctional mitochondria, disorganization of sarcomere structure,
and age-related cardiomyopathy in Atg5-deficient mice
[41]
(b) ↓ cardiac function and survival in Parkin-deficient mice [42]
(c) Stimulation of mitophagy with spermidine, a natural polyamine, preserves cardiac function in old mice [43, 44]
(d) Inhibition of miR-22 rescues autophagy and improves cardiac function in old mice [45, 46]
(ii) Alterations of the inflammatory, endothelial, and myogenic phenotype of cardiac cells are also observed, with most
of changes related to the aging-dependent manifestation of mutations in genes involved in the calcium cycling and
signaling (↓ activity of SERCA2 and calsequestrin and Ica)
[47, 48]
(iii) ↓ cardiac sympathetic innervation
[49, 50](a) ↓ catecholamine uptake, ↓ isoproterenol response, ↓ epinephrine reuptake, and ↓ noradrenalin transport in
senescent cardiac neuronal cells
(iv) Age-dependent hERG mutations
[51]
(a) Disorganization of the structure of the sarcomeric structure and myofibrillary proteins
(v) ↓ SIRT 3
[52]
(a) Pericyte loss and endothelial dysfunction, further exacerbated in the case of concomitant diabetic condition
(vi) ↑ ADAM/TACE overexpression in adipose tissue, mediated by ↓ negative regulation by caveolin-1
[53]
(a) ↑ TNF-α activity
(vii) ↑ senescence-associated genetic program in recruited fibroblasts of cardiac ischemia can be considered a
protective mechanism from endothelin-1-mediated cardiac fibrosis
[54, 55]
SERCA2: sarcoplasmic reticulum calcium adenosine triphosphatase; Ica: L-type calcium current; hERG: human K+ channel ether-à-go-go; SIRT3:
mitochondrial nicotinamide adenine nucleotide histone deacetylase.
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particularly poor of fibroblasts [79]. Conversely, mamma-
lians have a higher fibroblast/cardiomyocyte ratio; thus, the
upregulation of genes involved in ECM synthesis and a
strong immunoinflammatory response dictate the outcome
of the damage response towards a scar formation.
4. Senescence Events in the Endogenous Stem
Reservoirs of the Heart and in Cardiac
Cell Therapy
From their discovery, cardiac stem cells have been studied
intensively to develop cardiac cell therapies for treating organ
failure. Cardiac stem cells can be cultured in vitro through the
generation of cardiospheres (CS) and then expanded serially
as cardiosphere-derived cells (CDCs) for clinical application
[66–69]. As with the other differentiated cells of the heart,
also cardiac stem cells might undergo senescence, showing
reduced telomere length and telomerase activity, expression
of p16INKA and p21CIP, and an IL-6- and IGFBP7-enriched
SASP [80].
The molecular mechanism for the onset of senescence in
these cells is still not completely elucidated. The cardiac niche
is rich in fibronectin and thus should represent a protective
environment, which, evidently, does not exclude stem cell
conditioning by aging-inducing triggers. In addition, also
the niche ECM is a potential target of aging.
Independently from their localization, senescent stem
cells tend to accumulate during aging. Nakamura et al. have
shown that an increased expression of the Wnt inhibitor
Sfrp1, together with higher levels of p16 and a peculiar SASP,
is typical of human CDCs of old subjects (65–83 years), in
comparison to those derived from younger ones (2–65 years)
[81]. A recent study by Piegari et al. evidenced that the anti-
tumoral drug doxorubicin exerts its cardiotoxicity also in
cardiac stem cells by inducing cardiac stem cell senescence.
In fact, telomere shortening, impaired migration, and differ-
entiation were demonstrated in the anthracycline-treated
human cells [82]. In addition, their number, self-renewing,
and clonogenicity abilities decrease during age-related
cardiovascular pathologies, compromising heart function
[35, 80, 83–85]. Interestingly, Wu et al. recently demon-
strated in a mouse model that although aged animals in phys-
iological settings possess a remarkable number of cardiac
stem cells, these ones result dysfunctional in several biologi-
cal activities, as the metabolism of vitamins and tyrosine,
the circadian rhythm, and the complement and coagulation
cascades. Consequently, cell proliferation, multipotency,
and differentiation abilities are impaired [86].
Besides anthracycline-induced damage, a strong body of
evidence suggests that other epigenetic modifications are
introduced in cardiac stem cells undergoing senescence [87].
Apart from resident stem cells of the heart, senescence
can affect also exogenous reservoirs, which are used for phys-
iological and pathological heart remodeling and have been
studied to develop new stem cell-based therapies. Hemato-
poietic stem cells (HSC) have, in fact, been widely applied
for this aim, since they are relatively easy to select through
a consolidated profile of surface differentiation markers used
for cytofluorimetric cell sorting [88]. These cells reside in the
bone marrow and can be mobilized in response to a variety of
signals [89]. Induced quiescence, overexpression of Mdr1
and Abcg2 transporters, glycolysis-mediated ATP genera-
tion, telomere shortening, accumulated mitochondrial muta-
tions, and reduced ROS production collectively turn these
cells into a senescent state, without sustained abilities of
self-renewal and differentiation [90–93]. Intriguingly,
although a high number of HSCs is retrieved in the elderly
heart, these undergo a drastic lowering of clonal diversity
and switch towards the myeloid lineage, consequently
impairing their regenerative abilities [94]. Early committed,
mobilized HSCs, that is, endothelial progenitor cells (EPCs),
might also display senescent features, for example, intensified
ROS production prompted by overexpressed angiotensin II
and increased induction of apoptosis, which can be both
potentially associated with reduced levels of SDF-1 [95, 96].
In support of HSC performance, mesenchymal stem cells
(MSCs), which were originally thought to reside in the bone
marrow alone, can be found in a variety of different tissues
and have been widely studied to perform cell therapies.
For example, the control of adipose stromal cell (ASC) fate
by epigenetic regulators might be an interesting tool to
boost both cardiac commitment and regenerative capacities
of these cells. Aged MSCs show a classic senescent phenotype
and demonstrate reduced migration capacity, decreased
plasticity [97], and alterations in their immunoregulatory
abilities, that is, one of the most striking properties of these
cells [88, 98–100].
Table 3 presents a summary of the altered character-
istics of CSCs, CDCs, HSCs, EPCs, and MSCs during
cell senescence.
5. Rejuvenation Biotechnology: Antisenescence
Regenerative Therapies and
Disease Modeling
Even though senescence was initially depicted as a beneficial
program activated by the organism to eliminate aged, dys-
functional mutated cells, scientists are still debating its true
biological significance [3, 80, 101, 102].
Cell clearance is the last and most critical stage of senes-
cence progression. As mentioned before, aged cardiovascular
tissues are incredibly enriched in differentiated as well as
stem/progenitor senescent cells. Moreover, cell clearance
has been related to regression of several diseases, as neurode-
generative disorders and cancer [103, 104].
It has been shown that in senescent cancer tissues,
cell clearance is impaired due to mutation in cell cycle
checkpoint-related genes, for example, p53, with severe
deleterious effects on tumor progression [105].
Indeed, it is fascinating that evolutionarily inferior organ-
isms, as the unicellular ciliate protozoa and the multicellular
basal metazoans, sponges, cnidarians, and flatworms, do not
show senescence and are able to remain in a quasi-immortal
state [106], firstly defined by Finch in 1994 as negligible
senescence [107]. A few years later, de Grey et al. intro-
duced the concept of engineered negligible senescence, as
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to encompass all the biomedical strategies applied to reach
a body rejuvenation in complex organisms, as the higher
bilaterians [108].
In the quest of heart immortality, several therapeutic
approaches have been explored, such as new drug genera-
tions, cardiac cell therapies, and tissue engineering strategies
(Table 4).
Naturally inspired drugs have been formulated by the
direct observation of the molecular pathways involved in
senescence. Demaria et al. demonstrated that the administra-
tion of recombinant platelet-derived growth factor-AA
(PDGF-AA), typically present in SASP secretome, could
accelerate wound healing in a mouse model of impaired
tissue repair [101].
Moreover, inhibitors of genetic pathways involved in
senescence-related apoptosis have revealed senolytic activity.
For example, it has been shown that the antitumoral agent
panobinostat is able to target accumulated senescent cells
for their effective clearance. This inhibitor of the histone dea-
cetylases has received FDA approval for the treatment of sev-
eral malignancies [109].
Similarly, desatinib and quercetin can act in concert to
clear senescent adipocyte and endothelial cells in atheroscle-
rotic lesions, by inhibiting the cell death regulator Bcl-2
Table 3: Senescence in endogenous stem reservoirs of the heart and in cardiac cell therapy.
CSCs and CDCs
(i) Signs of senescence
(a) Reduced telomere length
[80]
(b) Decreased telomerase activity
(c) Reduced expression of p16INKA and p21CIP
(d) Decreased expression of IL-6- and IGFBP7-enriched SASP
(e) Increased expression of the Wnt inhibitor Sfrp1and of p16 and a peculiar SASP typical in old subjects
(65–83 years), differently from younger ones (2–65 years)
[81]
(ii) Known senescent triggers
(a) Age-related cardiovascular pathologies, compromising heart function [83–85]
(b) Antitumoral drugs, as anthracyclines [82]
(c) Aged animals in physiological settings possess a remarkable number of cardiac stem cells, but dysfunctional
in several biological activities, as the metabolism of vitamins and tyrosine, the circadian rhythm, and the complement
and coagulation cascades. Consequently, cell proliferation, multipotency, and differentiation abilities are impaired
[86]
(d) Epigenetic modifications [87]
HSC
(i) Signs of senescence
(a) Induced quiescence
[90–93]
(b) Overexpression of Mdr1 and Abcg2 transporters
(c) Glycolysis-mediated ATP generation
(d) Telomere shortening
(e) Accumulated mitochondrial mutations
(f) Reduced ROS production
(g) Reduced abilities of self-renewal and differentiation
(h) Although a high number of HSCs is retrieved in the elderly heart, these undergo a drastic lowering of clonal
diversity and switch towards the myeloid lineage, consequently impairing their regenerative abilities
[94]
EPCs
(i) Signs of senescence
(a) Overexpressed angiotensin II
[95, 96]
(b) Increased induction of apoptosis
(c) Reduced levels of SDF-1
(d) Intensified ROS production
MSCs
(i) Signs of senescence
(a) Classic senescent phenotype
(b) Reduced migration capacity [97]
(c) Decreased plasticity
(d) Alterations in immunoregulatory abilities [88, 98–100]
CSC: cardiac stem cells; CDCs: cardiosphere-derived cells; HSCs: hematopoietic stem cells; EPCs: endothelial progenitor cells; MSCs: mesenchymal stem cells.
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[110]. BH3 mimetic inhibitors acting on the same gene, as
ABT-199, ABT-263, and ABT-737, induce the clearance of
senescent HSC and consequently increase the proliferation
of the healthy ones [111].
Administration of exogenous IL-10 is particularly benefi-
cial in the clinical treatment of myocardial infarction. In fact,
Jung et al. verified that IL-10, an anti-inflammatory cytokine
secreted by M2 macrophages, is able to stimulate the mono-
cyte polarization towards the regenerative profile and the
activation of fibroblasts, with consequent positive effects on
left ventricle function and dilatation [112]. A similar effect
can also be achieved by conditioning with activators of
SIRT-1 [113]. Analogously, age-related cardiac hypertrophy
has been reversed by intraperitoneal injection of recombi-
nant GDF11, a member of the TGF-β growth factor
superfamily [114].
For the reversal of endothelial cell senescence in athero-
sclerosis and other pathologies, the administration of a
bactericidal/permeability-increasing fold-containing family
B member 4 (BPIFB4) isoform has demonstrated to increase
Table 4: Current approaches of rejuvenation biotechnology.
Naturally inspired novel drug generations
(i) rPDGF-AA might accelerate wound healing in a mouse model of impaired tissue repair. [101]
(ii) FDA-approved antitumoral agent panobinostat is able to target accumulated senescent cells for their
effective clearance.
[109]
(iii) Desatinib and quercetin clear senescent adipocyte and endothelial cells in atherosclerotic lesions. BH3 mimetic
inhibitors, as ABT-199, ABT-263, and ABT-737, induce the clearance of senescent HSC and consequently
increase the proliferation of the healthy ones.
[110, 111]
(iv) Administration of exogenous IL-10 or activators of SIRT-1 is particularly beneficial in the clinical treatment of
myocardial infarction, by acting on the macrophages/fibroblast axis.
[112, 113]
(v) Intraperitoneal injection of recombinant GDF11 reverses age-related cardiac hypertrophy. [114]
(vi) Administration of BPIFB4 increases the production of NO and stimulates relaxation, reversing endothelial cell
senescence in atherosclerosis and other pathologies.
[115–119]
Stem cells for senescence protection
(i) Fetal MSCs secrete bioactive factors promoting proliferation and differentiation in aged MSCs. [120]
(ii) MSC secretome has beneficial effects in the protection, differentiation, and regeneration of CSCs and ancillary
cellular elements.
[121]
(iii) CSCs ameliorate cardiac functionality in the anthracycline-induced cardiomyopathic heart. [113]
(iv) A significant positive correlation exists between BB treatment of donor patients and both successful CS isolation
and CS-forming cells yield from primary explant cultures. A significantly faster and higher CS-forming capacity
was detectable in BB explants compared to NBB. A significantly increased percentage of CD90+ cells was observed
in NBB CDCs.
[122]
(v) CD90 expression in injected CDCs negatively correlated with infarct scar size reduction (CADUCEUS trial). This
study supports the possible predictive and adjuvant role of β-blocker treatment in cardiac cell therapy applications,
as recently suggested for MSC-based therapies. It also suggests novel insights on the influence of BB treatments on
the quality and abundance of the cardiac reparative cellular pool.
[123, 124]
Stem cell engineering and reprogramming strategies
(i) Resveratrol/rapamycin induces an epigenetic cellular reprogramming in senescent CSCs derived from decompensated
hearts, by increasing cell proliferation.
[125]
(ii) PIM overexpression in senescent CSCs reverses heart aging. [126]
(iii) Pluripotency reprogramming is feasible in centenarian cardiac fibroblasts by OCT4, SOX2, c-MYC, KLF4, NANOG,
and LIN28 overexpression.
[129]
(iv) Treatment with inhibitors of BMP-SMAD signaling, for example, Dorsomorphin, SMAD6, and SMAD7, generates
iPSCs in p16-mediated senescent fibroblasts.
[130]
In vitro 3D tissue engineering platforms to model senescence and aging
(i) Evaluation of the effect of oxidative stress on a bioengineered tissue, constructed with a decellularized, MSC-secreted
ECM scaffold and human umbilical cord-derived MSC. By comparison to an artificial matrix layer in fibronectin
and collagen I, cells seeded onto decellularized scaffolds are less incline to develop senescence after H202 stimulation,
through an effect mediated by SIRT-1 upregulation.
[131]
(ii) Age of cardiac fibroblasts is a determining factor in the electrical and mechanical performance of cocultured
cardiomyocytes in an in vitro 3D cardiac tissue, composed of a mixture of hydrogel and fibroblasts in molds of
polidymethylsiloxane. This model is useful to recapitulate in vitro the alterations observed in senescent fibroblasts
of the adult heart.
[132]
rPDGF-AA: recombinant platelet-derived growth factor-AA; BPIFB4: bactericidal/permeability-increasing fold-containing family B member 4; MSCs:
mesenchymal stem cells; CSCs: cardiac stem cells; CSs: cardiospheres; BB: β-blocker; NBB: non-β-blocker; iPSCs: induced pluripotent stem cells; ECM:
extracellular matrix.
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the production of NO and stimulates relaxation, as shown by
the work of Puca’s group [115–119].
Apart from targeting molecular pathways, further strat-
egies to enable senescence protection are represented by
the use of different stem cells. Fetal MSC have been con-
firmed to secrete bioactive factors able to promote prolif-
eration and differentiation in aged MSC [120]. This is
particularly relevant in therapies based on adult MSC in
order to protect these cells from possible senescence trig-
gers in unfavorable microenvironments. Beneficial effects
of MSC secretome are also being exploited in a recent bio-
medical approach, combining cardiac stem cells and ancillary
cellular elements to increase their protection, differentiation,
and regeneration [121].
In addition, cardiac stem cells are being infused also in
the hostile microenvironment offered by the anthracycline-
induced cardiomyopathic heart, whose compromised
functions have been ameliorated with this therapeutic
approach [113].
We recently described for the first time a significant
positive correlation between β-blocker (BB) treatment of
donor patients and both successful CS isolation and CS-
forming cell yield from primary explant cultures. Our
results show profound differences in cell phenotype based
on their isolation from either BB- or non-β-blocker-
treated (NBB) patients. In fact, a significantly faster and
higher CS-forming capacity was detectable in BB explants
compared to NBB. Moreover, an immunophenotypical
shift of the described CDC marker CD90 was detectable
between the two groups, with a significantly increased per-
centage of CD90+ cells in NBB [122]. In the CADUCEUS
clinical trial, CD90 expression in injected CDCs negatively
correlated with infarct scar size reduction. This study
supports the possible predictive and adjuvant role of β-
blocker treatment in cardiac cell therapy applications, as
recently suggested for mesenchymal stem cell-based thera-
pies. It also suggests novel insights on the influence of BB
treatments on the quality and abundance of the cardiac
reparative cellular pool [123, 124].
In order to increase the therapeutic success of cardiac
stem cell therapies in elderly patients, genetic engineering
might be a valid tool too. Avolio et al. have proven that the
resveratrol/rapamycin combined treatment of senescent car-
diac stem cells derived from decompensated hearts generates
an epigenetic cellular reprogramming that reverses the aged
phenotype and increases the proliferation [125]. The overex-
pression of Pim-1 was shown to have analogous effects in
senescent cardiac stem cells [126]. The reprogramming
approach to pluripotency is a promising powerful strategy
to overcome senescence. Yamanaka and his group demon-
strated as first the feasibility to convert somatic differentiated
cells into induced pluripotent stem cells (iPSCs) by the over-
expression of four transcription factors, that is, OCT4, SOX2,
c-MYC, and KLF4 [127, 128]. Strikingly, Lapasset et al.
induced the pluripotency state in senescent and centenarian
fibroblasts, by adding NANOG and LIN28 to the reprogram-
ming gene cocktail used before [129].
Interestingly, the treatment of p16-mediated senescent
fibroblasts with inhibitors of BMP-SMAD signaling (e.g.,
Dorsomorphin, SMAD6, and SMAD7) is able to favor the
generation of iPSCs [130].
Lastly, the creation of platforms to model senescence and
aging in a tridimensional (3D) tissue environment is of
paramount importance to better simulate cell-ECM interac-
tions and develop clinically relevant therapeutic solutions.
Recently, two research groups have demonstrated the fea-
sibility to model senescence in 3D settings. Zhou et al.
evaluated the effect of oxidative stress on a bioengineered tis-
sue, constructed with a decellularized, MSC-secreted ECM
scaffold and human umbilical cord-derived MSC. By com-
parison to an artificial matrix layer realized with fibronectin
and collagen I, the authors showed that cells seeded onto
decellularized scaffolds are less incline to develop senescence
after H202 stimulation, through an effect mediated by SIRT-1
upregulation [131].
Li et al. reconstructed in vitro a 3D cardiac tissue by
injecting a mixture of hydrogel, neonatal rat ventricular
cardiomyocytes, and fibroblasts in molds of polidymethyl-
siloxane. They revealed that the age of cardiac fibroblasts
is a determining factor in the electrical and mechanical
performance of cocultured cardiomyocytes [132], by reca-
pitulating in vitro the alterations observed in senescent
fibroblasts of the adult heart.
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